Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis

PHASE3CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

November 22, 2022

Study Completion Date

January 17, 2023

Conditions
COVID-19
Interventions
DRUG

Double-Stranded RNA sodium salt

Once intramuscular injection 5 mg (1 vial)

DRUG

Placebo

Once intramuscular injection (1 vial)

Trial Locations (10)

Unknown

Regional Budgetary Healthcare Institution Ivanovo Clinical Hospital, Ivanovo

Federal State Budgetary Educational Institution of Higher Education Kirov State Medical University of Ministry of Health of the Russian Federation, Kirov

State Budgetary Healthcare Institution of Moscow Municipal Clinical Hospital Named after S. I. Spasokukotsky of Moscow Healthcare Department, Moscow

Professorskaya Klinika LLC, Perm

Avrora MedFort LLC, Saint Petersburg

Eco-Safety R&D Centre LLC, Saint Petersburg

OrCli Hospital LLC, Saint Petersburg

Federal State Budgetary Educational Institution of Higher Education N. P. Ogarev Mordovia State University, Saransk

Federal State Budgetary Educational Institution of Higher Education Smolensk State Medical University of Ministry of Health of the Russian Federation Principal Investigator Kozlov Roman Sergeevich, Smolensk

Regional State Budgetary Healthcare Institution Clinical Hospital No. 1, Smolensk

All Listed Sponsors
lead

Promomed, LLC

OTHER